Any-grade TRAEs reported in greater than or equal to 10% of patients who received treatment and grade 3/4 TRAEs in all patients with R/R PMBL who received treatment
| Any-grade TRAEs reported in ≥ 10% patients who received treatment, and grade 3/4 TRAEs in any patients, n (%) . | Any grade . | Grade 3/4 . |
|---|---|---|
| Total | 25 (83.3) | 16 (53.3) |
| Neutropenia | 14 (43.3) | 13 (40.0) |
| Pyrexia | 9 (30.0) | 1 (3.3) |
| Arthralgia | 6 (20.0) | 0 |
| Thrombocytopenia | 5 (16.7) | 3 (10.0) |
| Rash | 5 (16.7) | 1 (3.3) |
| Peripheral sensory neuropathy | 5 (16.7) | 0 |
| Peripheral neuropathy | 4 (13.3) | 3 (10.0) |
| Hyperthyroidism | 4 (13.3) | 0 |
| Decreased neutrophil count | 2 (6.7) | 2 (6.7) |
| Colitis | 1 (3.3) | 1 (3.3) |
| Immune-mediated hepatitis | 1 (3.3) | 1 (3.3) |
| Maculopapular rash | 1 (3.3) | 1 (3.3) |
| Any-grade TRAEs reported in ≥ 10% patients who received treatment, and grade 3/4 TRAEs in any patients, n (%) . | Any grade . | Grade 3/4 . |
|---|---|---|
| Total | 25 (83.3) | 16 (53.3) |
| Neutropenia | 14 (43.3) | 13 (40.0) |
| Pyrexia | 9 (30.0) | 1 (3.3) |
| Arthralgia | 6 (20.0) | 0 |
| Thrombocytopenia | 5 (16.7) | 3 (10.0) |
| Rash | 5 (16.7) | 1 (3.3) |
| Peripheral sensory neuropathy | 5 (16.7) | 0 |
| Peripheral neuropathy | 4 (13.3) | 3 (10.0) |
| Hyperthyroidism | 4 (13.3) | 0 |
| Decreased neutrophil count | 2 (6.7) | 2 (6.7) |
| Colitis | 1 (3.3) | 1 (3.3) |
| Immune-mediated hepatitis | 1 (3.3) | 1 (3.3) |
| Maculopapular rash | 1 (3.3) | 1 (3.3) |